Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Gockerman
J P
JP
Silberman
H
H
Bartolucci
A A
AA
D015250:Aclarubicin; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015250:Aclarubicin